Your browser doesn't support javascript.
Human induced pluripotent stem cell­derived mesenchymal stem cells alleviate atherosclerosis by modulating inflammatory responses.
Mol Med Rep ; 17(1): 1461-1468, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29257199
The transplantation of mesenchymal stem cells (MSCs) has been a reported method for alleviating atherosclerosis (AS). Because the availability of bone marrow­derived MSCs (BM­MSCs) is limited, the authors used this study to explore the use of a new type of MSC, human induced pluripotent stem cell­derived MSCs (iPSC­MSCs), to evaluate whether these cells could alleviate AS. iPSC­MSCs were intravenously administered to ApoE knock out mice fed on a high­fat diet (HFD) for 12 weeks. It was reported that systematically administering iPSC­MSCs clearly reduced the size of plaques. In addition, the numbers of macrophages and lipids in plaques were lower in the HFD + iPSC­MSCs group than in the HFD group. Furthermore, iPSC­MSCs attenuated AS­associated inflammation by decreasing the levels of inflammatory cytokines, such as tumor necrosis factor­α and interleukin­6, in serum. In addition, the expression of Notch1 was higher in the HFD group, and injecting iPSC­MSCs reversed this effect. In conclusion, the current study provides the first evidence indicating that iPSC­MSCs may be a new optional MSC­based strategy for treating AS.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Mesenquimais / Aterosclerose / Células-Tronco Pluripotentes Induzidas / Células-Tronco Mesenquimais Limite: Animais / Humanos / Masculino Idioma: Inglês Revista: Mol Med Rep Ano de publicação: 2018 Tipo de documento: Artigo